FRANKFURT (Reuters) - Germany’s Probiodrug AG, a developer of treatments for Alzheimer’s disease plans to list its shares in Amsterdam via an initial public offer (IPO), it said on Thursday, adding to the growing number of European biotech firms looking to share markets to raise new funds.
It is working on drugs to slow or halt the progression of Alzheimer as opposed to available treatments which mainly address the symptoms of cognitive decline, Probiodrug said in a statement.
